Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics ( (CLDI) ) has issued an announcement.
On March 27, 2026, Calidi Biotherapeutics reported fourth-quarter and full-year 2025 results, highlighting scientific and clinical progress alongside continued losses as it advances its oncology pipeline. The company formed a partnership with Avance Clinical in Australia to rapidly initiate a first-in-human trial of its lead oncolytic virus CLD-401 and reported supportive FDA Type D feedback as it works toward an IND filing by the end of 2026.
Calidi also entered a GMP manufacturing agreement with Matica Bio for CLD-401, presented new data on in situ T-cell engagers from its RedTail platform at the 2026 AACR-IO conference, and raised $6.5 million through an underwritten offering and ATM sales to extend its cash runway. For 2025, Calidi posted a net loss attributable to common stockholders of $25.6 million, modestly higher than 2024, with increased R&D spending, lower general and administrative costs, and cash declining to $5.6 million at year-end, underscoring its dependence on additional financing as it moves toward clinical trials.
The most recent analyst rating on (CLDI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
The score is held down primarily by persistent losses and significant cash burn with no revenue base, despite improved leverage and positive equity. Technicals also remain broadly bearish (below key moving averages and negative MACD), while corporate events provide a modest offset through financing and encouraging preclinical progress. Valuation contributes little given the negative P/E and no dividend yield.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics Inc. is a San Diego-based biotechnology company focused on developing targeted genetic medicines for cancer using its proprietary RedTail platform, an engineered enveloped oncolytic virus designed for systemic delivery to metastatic tumor sites. Lead candidate CLD-401, now in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer and other high-need tumors, and the company is also advancing in situ T-cell engager approaches for solid tumors.
The RedTail technology is intended to shield therapeutic viruses from immune clearance, enabling them to reach tumors, induce tumor lysis and deliver genetic payloads directly within the tumor microenvironment. Calidi, listed on the NYSE American under ticker CLDI, is positioning this platform to address solid tumors where conventional therapies and existing T-cell engager strategies have shown limitations.
Average Trading Volume: 216,120
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.07M
See more data about CLDI stock on TipRanks’ Stock Analysis page.